



## Bulletin from the annual general meeting of Alzinova AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Alzinova AB (publ) (the “Company”) on 30 May 2023 in Gothenburg.

### **Adoption of income statement and balance sheet and discharge from liability**

The AGM resolved to adopt the income statement for the financial year 2022 as well as the balance sheet as of 31 December 2022. The members of the Board of Directors and the managing director were discharged from liability for the financial year 2022.

### **Allocation of profit or loss**

The AGM resolved, in accordance with the Board of Directors’ proposal, that no dividend shall be paid for 2022 and that the results of the Company shall be carried forward.

### **Board of Directors and auditor**

The AGM resolved, in accordance with the Nomination Committee’s proposal, on re-election of Anders Blom, Lena Degling Wikingsson, Per-Göran Gillberg, Clas Malmeström, Carol Routledge, and Anders Waas, and new election of Julian Aleksov, as Board members. Furthermore, the Deputy Board member Anders Sandberg was re-elected. Julian Aleksov was elected as the chairman of the Board of Directors. The AGM re-elected the audit firm Ernst & Young Aktiebolag as auditor.

The AGM further resolved on remuneration to the Board of Directors in accordance with the Nomination Committee’s proposal. The AGM furthermore resolved in accordance with the Nomination Committee’s proposal, that remuneration to the auditor shall be paid in accordance with approved statement of costs.

### **Authorisation to issue new shares and/or warrants**

The AGM resolved, in accordance with the Board of Directors’ proposal, to authorise the Board of Directors to, at one or several occasions and for the period up until the next annual general meeting, resolve to increase the Company’s share capital by issuing new shares or warrants. Such issue resolution may be carried out with or without deviation from the shareholders’ preferential rights and with or without provisions for contribution in kind, set-off or other conditions.

The total number of shares that may be issued, or in the event of an issue of warrants, added after exercise, with the support of the authorisation shall not be limited in any other way than by the limits for the share capital and number of shares, as set forth from time to time in the registered Articles of Association.



The reason for the proposal and the possibility of deviation from the shareholders' pre-emption rights is to broaden and strengthen the ownership with strategic shareholders, procuring or facilitating the procurement of working capital, increasing the liquidity of the share, making acquisitions, or procuring or facilitating the procurement of capital for acquisitions.

"Björn Larsson has contributed greatly to Alzinova's development during his time as Chairman of the Board and I am honored to have been entrusted to take over this important role", says Julian Aleksov, incoming Chairman of the Board of Alzinova

**For more information, please contact:**

Kristina Torfgård, CEO

Tel. +46 708 46 79 75

E-mail: [kristina.torfgard@alzinova.com](mailto:kristina.torfgard@alzinova.com)

*Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.*

**About Alzinova**

Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer's disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova's proprietary A $\beta$ CC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer's is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company's Certified Adviser on Nasdaq First North Growth Market is Redeye AB. For more information about Alzinova, please visit: [www.alzinova.com](http://www.alzinova.com)

**Attachments**

**Bulletin from the annual general meeting of Alzinova AB (publ)**